linjc16/ctgov huggingface dataset:
Establishment of a Creatinine Clearance Estimation Equation and Daily Creatinine Excretion Reference Table for Taiwanese

Study Overview
=================
Brief Summary
-----------------
It's important to dose according to renal function in who has impaired kidney function. There are two common methods estimating renal function: one is creatinine clearance estimated by Cockcroft-Gault (CG) equation; another is glomerular filtration rate estimated by Modification of Diet in Renal Disease (MDRD) equation. The previous study (not published) showed that CG underestimated 24 hour measured urine creatinine clearance by our team. The difference may be due to ethnicity. Thus we want to establish a estimated creatinine clearance equation fitting in Taiwanese. Besides, there are lots of studies discussing difference between CG and MDRD. We have found that MDRD overestimated CG in patients who were older or thin. Therefore, we want to analysis which characteristics of patients the difference are largest or smallest.

Official Title
-----------------
Establishment of a Creatinine Clearance Estimation Equation and Daily Creatinine Excretion Reference Table for Taiwanese

Conditions
-----------------
Estimated Creatinine Clearance

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age above or equal to 20 year-old adults had 24 hour urine creatinine collection Exclusion Criteria: lack of at least one :sex, diagnosis, age,weight, height serum creatinine beyond linear test range with extreme weight or height with acute kidney injury or specific diagnosis with extremities of daily urine creatinine excretion

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Coefficient of determination of estimated creatinine clearance equation | Compare new estimated creatinine clearance equation for Taiwanese with Cockcroft-Gault equation | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Differences of daily urine creatinine excretion between Caucasian and Taiwanese |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
renal function, creatinine clearance
Multimodality Treatment Including Curative Resection of Advanced NSCLC

Study Overview
=================
Brief Summary
-----------------
This study retrospectively evaluates clinical parameters and outcome of patients with advanced stage non-small cell lung cancer treated with neoadjuvant therapy followed by curative-intent surgery at the Divison of Thoracic Surgery at the Medical University of Vienna

Detailed Description
-----------------
This study will be undertaken as a retrospective cohort study at Devision of Thoracic Surgery, Medical University of Vienna. All patients with non-small-cell lung cancer, who received an induction chemo- or chemoradiotherapy followed by surgery in a curative intention at the Devision of Thoracic Surgery, Medical University, will be included. The aim of this study is to evaluate peri- and postoperative clinical parameters and short- and long-term outcomes in patients.

Official Title
-----------------
Multimodality Treatment Including Curative Resection of Advanced Stage Non-small Cell Lung Cancer - an Explorative, Retrospective Pilot Study

Conditions
-----------------
Advanced Non-small-cell Lung Cancer

Intervention / Treatment
-----------------
* Other: Date collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with advanced NSCLC and multimodality treatment including curative-intent resection Exclusion Criteria: Patients with early stage NSCLC Patients with advanced NSCLC without multimodality treatment Patients without curative resection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Neoadjuvant chemoradiotherapy<br>Patients with advanced NSCLC treated with neoadjuvant platinum-based chemoradiotherapy followed by curative-intent surgery | Other: Date collection<br>* Retrospective data analysis<br>|
| Neoadjuvant chemotherapy<br>Patients with advanced NSCLC treated with neoadjuvant platinum-based chemotherapy followed by curative-intent surgery | Other: Date collection<br>* Retrospective data analysis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | Overall survival of stage III NSCLC in resectable patients undergoing induction treatment and curative intent surgery Overall survival of stage III NSCLC in resectable patients undergoing induction treatment and curative intent surgery Overall survival of stage III NSCLC in resectable patients undergoing induction treatment and curative intent surgery Overall survival of stage III NSCLC in resectable patients undergoing induction treatment and curative intent surgery | 18 years |
The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)

Study Overview
=================
Brief Summary
-----------------
Study to assess efficacy, tolerability and safety parameters of a three month ALNA®OCAS® -treatment with special respect to nocturia

Official Title
-----------------
The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)

Conditions
-----------------
Prostatic Hyperplasia

Intervention / Treatment
-----------------
* Drug: ALNA®OCAS®


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Indication for treatment with ALNA®OCAS® according to the prescribing information for a minimum period of three months Exclusion Criteria: Patients fulfilling one of the general or specific contraindications listed in the ALNA®OCAS® Summary of Product Characteristics (SPC), particularly patients with known hypersensitivities against tamsulosin hydrochloride or any other ingredient of the product, orthostatic dysregulation or severe liver insufficiency could not be included in the Post Marketing Study (PMS) study
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| BPH patients<br> | Drug: ALNA®OCAS®<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline in International Prostatic Symptom Score (IPSS) by means of a patient questionnaire |  | Baseline, after 3 months | 
| Change from Baseline in Nocturia quality of life by means of a patient questionnaire |  | Baseline, after 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline in Maximum urinary flow rate (Qmax) |  | Baseline, after 3 months | 
| Change from Baseline in residual urine volume |  | Baseline, after 3 months | 
| Assessment of tolerability by investigator on 4-point scale |  | after 3 months | 
| Number of patients with adverse events |  | up to 3 months |
Natural Course of Adhesive Capsulitis of Hip

Study Overview
=================
Brief Summary
-----------------
The purpose of this prospective study is to see the natural course of adhesive capsulitis of hip. The study is based on the hypothesis that the natural course of adhesive capsulitis of hip is similar to that of adhesive capsulitis of shoulder. This study is also based on a hypothesis that hip joint capsule stretching exercise will result in pain relief, recovery of hip range of motion in months.

Official Title
-----------------
Natural Course of Adhesive Capsulitis of Hip

Conditions
-----------------
Adhesive Capsulitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Painful hip with Limited range of motion (especially external rotation and abduction) Exclusion Criteria: Acute trauma history hematologic abnormality (Rheumatologic disease, Autoimmune disease) Radiologic abnormality (joint degenerative change, calcification, loosebody, evidence of Femoroacetabular impingement, osteonecrosis of femoral head, etc) MRI: Extra-articular pathology

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
adhesive capsulitis, hip
Prevalence of May-Thurner Syndrome in 1st-degree Relatives of Symptomatic Patients

Study Overview
=================
Brief Summary
-----------------
The aim is to assess the prevalence of May-Thurner syndrome in 1st-degree relatives of previously identified symptomatic patients.

Detailed Description
-----------------
May-Thurner syndrome (MTS) is a condition characterised by compression of the left common iliac vein by the right common iliac artery and the anterior spine of the 5th lumbar vertebrae. Previously thought to be a rare condition, the prevalence of MTS is thought to be underreported. MTS can lead to significant morbidity in the form of chronic venous insufficiency, venous ulceration, lower limb swelling, venous claudication, deep-vein thrombosis, varicose veins, pelvic congestion syndrome, chronic pelvic pain and chronic post-thrombotic syndrome. It is a known risk factor for development of venous incompetence and varicose veins in adolescents and young adults. Furthermore, it is known to be an a causative factor in the development of unprovoked DVT in younger patients, however data on the risk of development of DVT in MTS patients has to date, been unavailable. The pathogenesis of MTS is largely unknown and whilst the condition is known to be more prevalent in females, familial risk factors are largely unknown. To date, no studies have previously assessed the prevalence of MTS in relatives of those with the condition.

Official Title
-----------------
Prevalence of May-Thurner Syndrome in 1st-degree Relatives of Symptomatic Patients

Conditions
-----------------
May-Thurner Syndrome

Intervention / Treatment
-----------------
* Other: No Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Informed consent, first degree relative with symptomatic May-Thurner syndrome Exclusion Criteria: Those who not give informed consent to be contacted or to be scanned.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No Intervention|No Intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence Assessment | To assess the prevalence of May-Thurner syndrome amongst 1st-degree relatives of symptomatic individuals referred to the Vascular Department, University Hospital Limerick using duplex ultrasound imaging | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Venous Competence Assessment | To assess concomitant venous incompetence of the lower limb | 1 year |
a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to identify the pharmacokinetic differences between two oral forms of Tacrolimus and consequent nephrotoxicity.

Official Title
-----------------
a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients

Conditions
-----------------
Pharmacokinetics, Tacrolimus

Intervention / Treatment
-----------------
* Drug: Tacrolimus


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ABO-compatible renal transplant recipients Exclusion Criteria: multi-organ transplant HIV(+) donor or recipients history of malignancy other than skin cancer (except completely cured basal cell ca or squamous cell ca) more than three-fold increase in AST or ALT level for 28 days pregnancy lactation

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Tacrobell<br> | Drug: Tacrolimus<br> <br> |
| Active Comparator: Prograf<br> | Drug: Tacrolimus<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pharmacokinetics |  | at postoperative 10 14 days and at postoperative 6 months for crossover study |
Comparison of Water Sorption Capacity and the Composition of Bronchial Fluids of Healthy Persons and Patients With Chronic Obstructive Bronchitis (COPD)

Study Overview
=================
Brief Summary
-----------------
Pilot basic research study on the properties of bronchial mucus. Examination of the sorption and desorption properties, mucin concentration, and structure of the mucus from healthy airways compared to patients with Chronic Obstructive Pulmonary Disease (COPD).

Detailed Description
-----------------
Mucus, of the correct composition, maintains airway hydration and protects the airway from inhaled particles through mucociliary transport. In chronic inflammatory airway diseases such as COPD or cystic fibrosis, infectious agents, inflammatory cells and products of inflammation such as DNA, increase mucus viscosity which results in decreased mucociliary clearance of inhaled particles, increasing the likelihood of respiratory infections. This pilot study is planned as basic research on the properties of bronchial mucus. Water isotherms and efficient water activity (sorption and desorption) of the collected samples are examined in defined temperature and humidity settings using DVS Intrinsic (Dynamic Vapour Sorption System, Surface Measurement Systems, London, UK). Findings will provide insights into possible treatment programs targeted at altering specific mucus components.

Official Title
-----------------
Vergleich Der Wasseraufnahmefähigkeit Und Zusammensetzung Von Bronchialflüssigkeiten Von Gesunden Und Patienten Mit Chronisch Obstruktiver Bronchitis (COPD)

Conditions
-----------------
COPD, Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age>18 COPD or other disease requiring bronchoscopy or elective surgery Signed informed consent form Exclusion Criteria: Not able to consent Linguistic, cognitive, or other obstacles

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| COPD<br>Secretions are collected from Bronchoscopy in clinical routine in COPD patients | |
| lung healthy<br>Secretions are collected from Removal of endotracheal tubes after elective surgery in lung healthy patients | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sorption | Maximum water sorption per degree of saturation in percent of the dry mass weight of the mucus samples | 5 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
mucociliary clearance, mucus, sorption of water
Hydrogen Sulfide and Pulmonary Vascular Remodeling on HRCT in Patients With COPD

Study Overview
=================
Brief Summary
-----------------
HRCT was used to evaluate pulmonary vascular remodeling in COPD. The role of H2S in pulmonary vascular remodeling in COPD was analyzed, in order to provide a basis for seeking new therapeutic targets.

Detailed Description
-----------------
This study aimed to investigate the relationship between endogenous H2S and pulmonary vascular remodeling on HRCT in patients with COPD through the determination of H2S and its synthase mRNA levels in blood and pulmonary vessels by HRCT, to evaluate the role of H2S in pulmonary vascular remodeling in COPD and to provide a basis for seeking new therapeutic targets. This study had predictive value for clinical prognosis of patients. It had important clinical guiding significance and social and economic benefit to comprehensively understand the pathogenesis of COPD.

Official Title
-----------------
A Cross-sectional Study of Endogenous Hydrogen Sulfide and Pulmonary Vascular Remodeling on HRCT in Patients With Chronic Obstructive Pulmonary Disease

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients meet the GOLD 2016 guidelines for diagnostic criteria of COPD: dyspnea, chronic cough and/or sputum symptoms, exposure to risk factors, and pulmonary function after inhalation of bronchodilator with forced expiratory volume (FEV1)/forced vital capacity (FVC) < 70%. Exclusion Criteria: - 1. Other lung diseases such as pneumonia, lung cancer, tuberculosis, pulmonary embolism, heart diseases such as heart failure, ventricular septal defect, patent ductus arteriosus, thoracic deformity and pleural diseases. 2. Patients who are unable to understand and/or complete questionnaire.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| COPD patients<br>The COPD questionnaire was conducted to collect the data of lung function, echocardiography and blood gas analysis, and the pulmonary vessels of HRCT were determined. Blood samples were collected for H2S-related indicators detection. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma levels of H2S and its synthase nucleic acid and pulmonary vascular remodeling indexes on HRCT in COPD patients |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relationship between plasma H2S and its synthase nucleic acid levels and pulmonary vascular remodeling indexes on HRCT in patients with COPD |  | 1 year |
Phielix et al.: Hepatic Fat Content and Adipokines

Study Overview
=================
Brief Summary
-----------------
Thiazoledinediones decrease blood glucose by their insulin-sensitizing properties. Here the investigators examined whether pioglitazone (PIO) improves insulin sensitivity independently of glycemic control and whether adipokines or non-esterfied fatty acids (NEFA) serve as mediators.

Official Title
-----------------
Effects of Glimepiride Monotherapy Versus Combined Neteglinide-Pioglitazone Therapy on Insulin Sensitivity in Type 2 Diabetic Patients

Conditions
-----------------
Type 2 Diabetes Mellitus

Intervention / Treatment
-----------------
* Drug: Pioglitazone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: well controlled patients with type 2 diabetes (Hb1Ac < 8%) no insulin therapy no co-morbidities stable medication use for the last 6 months stable body weight the last 6 months no diet in the last 6 months Exclusion Criteria: Hb1Ac > 8% insulin therapy diabetes-related co-morbidities, like cardiovascular disease, neuropathology unstable medication use unstable body weight in the last 6 months (> 5 kg) following a diet in the last 6 months

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: control group<br>parallel group without intervention | Drug: Pioglitazone<br>* 12 weeks of pioglitazone treatment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| whole body insulin sensitivity | Participants underwent a two-step hyperinsulinemic euglycemic clamp to determine insulin sensitivity, expressed as rate of glucose disposal (Rd) in mg/kg/min. | within a minimal of 1 week before the start of the 12 weeks pioglitazone or glimepiride treatment and after the last day of the treatment period. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| intrahepatocellular lipid content | Liver proton-magnetic resonance spectroscopy was applied to determine liver fat (HCL) in % (relative to the water peak). | within a minimal of 1 week before the start of the 12 weeks pioglitazone or glimepiride treatment and after the last day of the treatment period. |